Top Midday Gainers

MT Newswires Live

May 29

Spero Therapeutics (SPRO) and GSK (GSK) said Wednesday that a phase 3 trial of tebipenem HBr, an investigational oral antibiotic for complicated urinary tract infections, including pyelonephritis, met its primary endpoint and will end early due to efficacy.

Shares of Spero catapulted 228% as intraday trading volume soared to over 166.9 million from a daily average of about 131,000.

Signing Day Sports (SGN) said Wednesday that it has signed a definitive business combination agreement to buy One Blockchain, the operating affiliate company of data hosting firm BlockchAIn Digital Infrastructure.

Shares of Signing Day soared 178%, with intraday trading volume at over 153.2 million compared with a daily average of roughly 1.7 million.

Aspire Biopharma (ASBP) said Wednesday it expects to launch Buzz Bomb, its sublingual pre-workout supplement, in Q3.

Shares surged 148% as intraday trading volume advanced to more than 567.3 million from a daily average of about 739,000.

Price: 2.24, Change: +1.56, Percent Change: +228.45

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2539403168"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2539403168\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2539403168?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-29 01:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2539403168","market":"sh","top_or_hot":-1,"title":"Top Midday Gainers","media":"MT Newswires Live","content":"<html><body><p> Spero <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (SPRO) and GSK (GSK) said Wednesday that a phase 3 trial of tebipenem HBr, an investigational oral antibiotic for complicated urinary tract infections, including pyelonephritis, met its primary endpoint and will end early due to efficacy.</p><p>Shares of Spero catapulted 228% as intraday trading volume soared to over 166.9 million from a daily average of about 131,000.</p><p>Signing Day Sports (SGN) said Wednesday that it has signed a definitive business combination agreement to buy One Blockchain, the operating affiliate company of data hosting firm BlockchAIn Digital Infrastructure.</p><p>Shares of Signing Day soared 178%, with intraday trading volume at over 153.2 million compared with a daily average of roughly 1.7 million.</p><p>Aspire Biopharma (ASBP) said Wednesday it expects to launch Buzz Bomb, its sublingual pre-workout supplement, in Q3.</p><p>Shares surged 148% as intraday trading volume advanced to more than 567.3 million from a daily average of about 739,000.</p><p>Price: 2.24, Change: +1.56, Percent Change: +228.45</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Top Midday Gainers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTop Midday Gainers\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-05-29 01:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Spero <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (SPRO) and GSK (GSK) said Wednesday that a phase 3 trial of tebipenem HBr, an investigational oral antibiotic for complicated urinary tract infections, including pyelonephritis, met its primary endpoint and will end early due to efficacy.</p><p>Shares of Spero catapulted 228% as intraday trading volume soared to over 166.9 million from a daily average of about 131,000.</p><p>Signing Day Sports (SGN) said Wednesday that it has signed a definitive business combination agreement to buy One Blockchain, the operating affiliate company of data hosting firm BlockchAIn Digital Infrastructure.</p><p>Shares of Signing Day soared 178%, with intraday trading volume at over 153.2 million compared with a daily average of roughly 1.7 million.</p><p>Aspire Biopharma (ASBP) said Wednesday it expects to launch Buzz Bomb, its sublingual pre-workout supplement, in Q3.</p><p>Shares surged 148% as intraday trading volume advanced to more than 567.3 million from a daily average of about 739,000.</p><p>Price: 2.24, Change: +1.56, Percent Change: +228.45</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2539403168","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2539403168","pubTimestamp":1748454295,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Spero Therapeutics (SPRO) and GSK (GSK) said Wednesday that a phase 3 trial of tebipenem HBr, an investigational oral antibiotic for complicated urinary tract infections, including pyelonephritis, met","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","GSK.UK":"葛兰素史克","BK4532":"文艺复兴科技持仓","BK4023":"应用软件","SGN":"Signing Day Sports, Inc.","BK4608":"AI应用概念股","LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK4007":"制药","SPRO":"Spero Therapeutics Inc.","ASBP":"Aspire Biopharma Holdings Inc.","BK4585":"ETF&股票定投概念","BK4588":"碎股","GSK":"葛兰素史克"},"translate_title":"午盘涨幅最大的股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASBP":0.9,"GSK":0.9,"GSK.UK":0.6,"SGN":0.9,"SPRO":0.9},"content_text":"Spero Therapeutics (SPRO) and GSK (GSK) said Wednesday that a phase 3 trial of tebipenem HBr, an investigational oral antibiotic for complicated urinary tract infections, including pyelonephritis, met its primary endpoint and will end early due to efficacy.Shares of Spero catapulted 228% as intraday trading volume soared to over 166.9 million from a daily average of about 131,000.Signing Day Sports (SGN) said Wednesday that it has signed a definitive business combination agreement to buy One Blockchain, the operating affiliate company of data hosting firm BlockchAIn Digital Infrastructure.Shares of Signing Day soared 178%, with intraday trading volume at over 153.2 million compared with a daily average of roughly 1.7 million.Aspire Biopharma (ASBP) said Wednesday it expects to launch Buzz Bomb, its sublingual pre-workout supplement, in Q3.Shares surged 148% as intraday trading volume advanced to more than 567.3 million from a daily average of about 739,000.Price: 2.24, Change: +1.56, Percent Change: +228.45","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}